Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Bausch Health: Dr. Yehia Hashad to join Bausch + Lomb as Chief Medical Officer » 07:11
01/20/22
01/20
07:11
01/20/22
07:11
BHC

Bausch Health

$25.57 /

-1.04 (-3.91%)

, ABBV

AbbVie

$135.21 /

-1.57 (-1.15%)

, NVS

Novartis

$88.85 /

-0.7 (-0.78%)

Bausch Health (BHC) has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NVS Novartis
$88.85 /

-0.7 (-0.78%)

BHC Bausch Health
$25.57 /

-1.04 (-3.91%)

ABBV AbbVie
$135.21 /

-1.57 (-1.15%)

BHC Bausch Health
$25.57 /

-1.04 (-3.91%)

11/03/21 JPMorgan
Bausch Health earnings selloff a buying opportunity, says JPMorgan
09/21/21 JPMorgan
Bausch has 50% upside based on sum-of-the-parts, says JPMorgan
08/04/21 JPMorgan
Bausch Health selloff on Solta IPO plans overdone, says JPMorgan
08/04/21 Barclays
Bausch Health price target lowered to $31 from $35 at Barclays
ABBV AbbVie
$135.21 /

-1.57 (-1.15%)

06:28 Today Barclays
AbbVie price target raised to $133 from $118 at Barclays
04:44 Today BMO Capital
Vertex upgraded to Outperform from Market Perform at BMO Capital
01/18/22 Cowen
AbbVie price target raised to $150 from $130 at Cowen
01/14/22 Piper Sandler
AbbVie approval comes with favorable label, says Piper Sandler
NVS Novartis
$88.85 /

-0.7 (-0.78%)

01/12/22 Alliance Global Partners
OpGen price target lowered to $3 from $4.35 at Alliance Global Partners
01/10/22 Citi
Novartis resumed with a Buy at Citi
01/06/22 Piper Sandler
Piper want to own Alnylam shares ahead of expected vutrisiran approval
12/15/21 Berenberg
Novartis price target lowered to CHF 85 from CHF 88 at Berenberg
NVS Novartis
$88.85 /

-0.7 (-0.78%)

BHC Bausch Health
$25.57 /

-1.04 (-3.91%)

ABBV AbbVie
$135.21 /

-1.57 (-1.15%)

NVS Novartis
$88.85 /

-0.7 (-0.78%)

BHC Bausch Health
$25.57 /

-1.04 (-3.91%)

ABBV AbbVie
$135.21 /

-1.57 (-1.15%)

NVS Novartis
$88.85 /

-0.7 (-0.78%)

BHC Bausch Health
$25.57 /

-1.04 (-3.91%)

ABBV AbbVie
$135.21 /

-1.57 (-1.15%)

NVS Novartis
$88.85 /

-0.7 (-0.78%)

BHC Bausch Health
$25.57 /

-1.04 (-3.91%)

ABBV AbbVie
$135.21 /

-1.57 (-1.15%)

Recommendations
AbbVie price target raised to $133 from $118 at Barclays » 06:28
01/20/22
01/20
06:28
01/20/22
06:28
ABBV

AbbVie

$135.21 /

-1.57 (-1.15%)

Barclays analyst Carter…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ABBV AbbVie
$135.21 /

-1.57 (-1.15%)

ABBV AbbVie
$135.21 /

-1.57 (-1.15%)

04:44 Today BMO Capital
Vertex upgraded to Outperform from Market Perform at BMO Capital
01/18/22 Cowen
AbbVie price target raised to $150 from $130 at Cowen
01/14/22 Piper Sandler
AbbVie approval comes with favorable label, says Piper Sandler
01/12/22 BMO Capital
AbbVie price target raised to $153 from $134 at BMO Capital
ABBV AbbVie
$135.21 /

-1.57 (-1.15%)

ABBV AbbVie
$135.21 /

-1.57 (-1.15%)

ABBV AbbVie
$135.21 /

-1.57 (-1.15%)

ABBV AbbVie
$135.21 /

-1.57 (-1.15%)

Upgrade
Vertex upgraded to Outperform from Market Perform at BMO Capital » 04:44
01/20/22
01/20
04:44
01/20/22
04:44
VRTX

Vertex Pharmaceuticals

$230.90 /

+0.17 (+0.07%)

, ABBV

AbbVie

$135.21 /

-1.57 (-1.15%)

BMO Capital analyst Evan…

BMO Capital analyst Evan Seigerman upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Market Perform with a price target of $274, up from $202. The analyst upgrades the shares ahead of the AbbVie (ABBV) cystic fibrosis data readout given his "increasingly positive outlook and the recent encouraging results" for VX-147. As the AbbVie data readout nears, Seigerman adds VX-147 to his model. He also thinks Vertex's pipeline outside of CTX001 and VX-147 "remains undervalued and could represent interesting upside if successful." Seigerman continues to believe Trikafta "sets a high threshold," with data from the new triple potentially raising the bar even higher which AbbVie is "unlikely to beat."

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$230.90 /

+0.17 (+0.07%)

ABBV AbbVie
$135.21 /

-1.57 (-1.15%)

VRTX Vertex Pharmaceuticals
$230.90 /

+0.17 (+0.07%)

01/10/22 Piper Sandler
Vertex Pharma's VX-880 data showed continued benefit, says Piper Sandler
12/15/21 Jefferies
Bloomin', Callaway, Newell among five 'Franchise Picks' additions at Jefferies
12/08/21 Wells Fargo
Vertex Pharmaceuticals initiated with an Overweight at Wells Fargo
12/02/21 RBC Capital
Vertex Pharmaceuticals price target raised to $265 from $250 at RBC Capital
ABBV AbbVie
$135.21 /

-1.57 (-1.15%)

01/18/22 Cowen
AbbVie price target raised to $150 from $130 at Cowen
01/14/22 Piper Sandler
AbbVie approval comes with favorable label, says Piper Sandler
01/12/22 BMO Capital
AbbVie price target raised to $153 from $134 at BMO Capital
01/11/22 Piper Sandler
AbbVie long range estimates need to come up, says Piper Sandler
VRTX Vertex Pharmaceuticals
$230.90 /

+0.17 (+0.07%)

ABBV AbbVie
$135.21 /

-1.57 (-1.15%)

VRTX Vertex Pharmaceuticals
$230.90 /

+0.17 (+0.07%)

ABBV AbbVie
$135.21 /

-1.57 (-1.15%)

VRTX Vertex Pharmaceuticals
$230.90 /

+0.17 (+0.07%)

ABBV AbbVie
$135.21 /

-1.57 (-1.15%)

VRTX Vertex Pharmaceuticals
$230.90 /

+0.17 (+0.07%)

ABBV AbbVie
$135.21 /

-1.57 (-1.15%)

Tuesday
Recommendations
AbbVie price target raised to $150 from $130 at Cowen » 07:29
01/18/22
01/18
07:29
01/18/22
07:29
ABBV

AbbVie

$135.93 /

+2.445 (+1.83%)

Cowen analyst Steve Scala…

Cowen analyst Steve Scala raised the firm's price target on AbbVie to $150 from $130 and keeps an Outperform rating on the shares. The analyst noted Rinvoq was approved in atopic dermatitis on Friday and he said his Rinvoq forecasts are below the company's guidance.

ShowHide Related Items >><<
ABBV AbbVie
$135.93 /

+2.445 (+1.83%)

ABBV AbbVie
$135.93 /

+2.445 (+1.83%)

01/14/22 Piper Sandler
AbbVie approval comes with favorable label, says Piper Sandler
01/12/22 BMO Capital
AbbVie price target raised to $153 from $134 at BMO Capital
01/11/22 Piper Sandler
AbbVie long range estimates need to come up, says Piper Sandler
01/05/22 Mizuho
Mizuho keeps AbbVie as top 2022 large cap pick, ups target
ABBV AbbVie
$135.93 /

+2.445 (+1.83%)

ABBV AbbVie
$135.93 /

+2.445 (+1.83%)

ABBV AbbVie
$135.93 /

+2.445 (+1.83%)

ABBV AbbVie
$135.93 /

+2.445 (+1.83%)

Friday
Recommendations
AbbVie approval comes with favorable label, says Piper Sandler » 15:02
01/14/22
01/14
15:02
01/14/22
15:02
ABBV

AbbVie

$135.38 /

+1.9 (+1.42%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond keeps an Overweight rating AbbVie shares with a $160 price target after the FDA approved Rinvoq with a "better than expected" atopic dermatitis label. "With what seems to be benign warning language and flexibility on dosing, we think the drug is now primed to capitalize on what has been largely positive dermatologist survey feedback regarding this opportunity," Raymond tells investors in a research note. The analyst says he would "not be shocked to see meaningful upside for the drug this year." Of his $2.15B fiscal 2022 U.S. revenue estimate for Rinvoq, Raymond notes that only $140M derives from atopic dermatitis.

ShowHide Related Items >><<
ABBV AbbVie
$135.38 /

+1.9 (+1.42%)

ABBV AbbVie
$135.38 /

+1.9 (+1.42%)

01/12/22 BMO Capital
AbbVie price target raised to $153 from $134 at BMO Capital
01/11/22 Piper Sandler
AbbVie long range estimates need to come up, says Piper Sandler
01/05/22 Mizuho
Mizuho keeps AbbVie as top 2022 large cap pick, ups target
01/03/22 Piper Sandler
AbbVie price target raised to $160 from $129 at Piper Sandler
ABBV AbbVie
$135.38 /

+1.9 (+1.42%)

ABBV AbbVie
$135.38 /

+1.9 (+1.42%)

ABBV AbbVie
$135.38 /

+1.9 (+1.42%)

ABBV AbbVie
$135.38 /

+1.9 (+1.42%)

Hot Stocks
AbbVie announces FDA approval of Rinvoq for atopic dermatitis » 13:12
01/14/22
01/14
13:12
01/14/22
13:12
ABBV

AbbVie

$132.91 /

-0.57 (-0.43%)

AbbVie announced the Food…

AbbVie announced the Food and Drug Administration has approved Rinvoq for the treatment of moderate to severe atopic dermatitis in adults and children 12 years of age and older whose disease did not respond to previous treatment and is not well controlled with other pills or injections, including biologic medicines, or when use of other pills or injections is not recommended.

ShowHide Related Items >><<
ABBV AbbVie
$132.91 /

-0.57 (-0.43%)

ABBV AbbVie
$132.91 /

-0.57 (-0.43%)

01/12/22 BMO Capital
AbbVie price target raised to $153 from $134 at BMO Capital
01/11/22 Piper Sandler
AbbVie long range estimates need to come up, says Piper Sandler
01/05/22 Mizuho
Mizuho keeps AbbVie as top 2022 large cap pick, ups target
01/03/22 Piper Sandler
AbbVie price target raised to $160 from $129 at Piper Sandler
ABBV AbbVie
$132.91 /

-0.57 (-0.43%)

ABBV AbbVie
$132.91 /

-0.57 (-0.43%)

ABBV AbbVie
$132.91 /

-0.57 (-0.43%)

ABBV AbbVie
$132.91 /

-0.57 (-0.43%)

Over a week ago
Conference/Events
JPMorgan to hold a virtual conference » 04:55
01/13/22
01/13
04:55
01/13/22
04:55
ABBV

AbbVie

$135.88 /

+0.24 (+0.18%)

, ALLO

Allogene Therapeutics

$12.32 /

-0.545 (-4.24%)

, BAX

Baxter

$86.43 /

+0.08 (+0.09%)

, BHG

Bright Health

$3.13 /

-0.085 (-2.65%)

, TWST

Twist Bioscience

$62.99 /

-4.11 (-6.13%)

, TXG

10x Genomics

$118.89 /

-2.99 (-2.45%)

, TDOC

Teladoc

$81.83 /

-4.47 (-5.18%)

, SRRK

Scholar Rock

$21.55 /

-0.53 (-2.40%)

, SLDB

Solid Biosciences

$1.49 /

-0.06 (-3.87%)

, RLAY

Relay Therapeutics

$26.12 /

-1.57 (-5.67%)

, QSI

Quantum-Si

$6.01 /

-0.28 (-4.45%)

, QDEL

Quidel

$124.62 /

-2.9099 (-2.28%)

, DAWN

Day One Biopharmaceuticals

$15.39 /

+0.28 (+1.85%)

, CERN

Cerner

$92.21 /

-0.04 (-0.04%)

, BRKR

Bruker

$73.60 /

+0.55 (+0.75%)

, BNTX

BioNTech

$221.16 /

+5.13 (+2.37%)

, BEAM

Beam Therapeutics

$70.23 /

-5.49 (-7.25%)

, MOR

MorphoSys

$8.99 /

-0.205 (-2.23%)

, MOLN

Molecular Partners

$27.00 /

+1.34 (+5.22%)

, MODV

ModivCare

$133.23 /

-1.36 (-1.01%)

, MYGN

Myriad Genetics

$26.17 /

-0.37 (-1.39%)

, CI

Cigna

$238.85 /

-1.1 (-0.46%)

, CRNX

Crinetics

$24.65 /

-0.85 (-3.33%)

, DNA

Ginkgo Bioworks

$6.26 /

-0.575 (-8.42%)

, ENDP

Endo

$3.54 /

-0.165 (-4.45%)

, JNJ

Johnson & Johnson

$169.83 /

-1.43 (-0.83%)

, GILD

Gilead

$72.24 /

-0.12 (-0.17%)

, HCAT

Health Catalyst

$33.50 /

-1.1 (-3.18%)

, HZNP

Horizon Therapeutics

$93.55 /

-2.38 (-2.48%)

, IART

Integra LifeSciences

$67.56 /

+0.36 (+0.54%)

, JAZZ

Jazz Pharmaceuticals

$144.87 /

-4.94 (-3.30%)

, IVA

Inventiva

$12.45 /

+ (+0.00%)

, ITOS

iTeos Therapeutics

$40.89 /

-0.64 (-1.54%)

, ITCI

Intra-Cellular

$39.77 /

-0.59 (-1.46%)

, MRNS

Marinus Pharmaceuticals

$10.85 /

-0.23 (-2.08%)

, NOVT

Novanta

$163.39 /

+0.07 (+0.04%)

, OMIC

Singular Genomics

$8.19 /

-0.35 (-4.10%)

, PACB

Pacific Biosciences

$14.46 /

-0.225 (-1.53%)

, RARE

Ultragenyx

$71.15 /

-1.64 (-2.25%)

, RAIN

Rain Therapeutics

$12.05 /

-0.83 (-6.44%)

, AMRS

Amyris

$5.28 /

+0.54 (+11.39%)

, ALKS

Alkermes

$24.24 /

-0.76 (-3.04%)

, NPCE

NeuroPace

$11.55 /

+0.8 (+7.44%)

, NVRO

Nevro

$90.88 /

-0.27 (-0.30%)

, SEER

Seer

$20.48 /

-0.03 (-0.15%)

, STTK

Shattuck Labs

$7.34 /

+0.06 (+0.82%)

, TLIS

Talis Biomedical

$3.24 /

-0.07 (-2.11%)

40th Annual Healthcare…

40th Annual Healthcare Virtual Conference to be held on January 10-13.Webcast Link

ShowHide Related Items >><<
TXG 10x Genomics
$118.89 /

-2.99 (-2.45%)

TWST Twist Bioscience
$62.99 /

-4.11 (-6.13%)

TLIS Talis Biomedical
$3.24 /

-0.07 (-2.11%)

TDOC Teladoc
$81.83 /

-4.47 (-5.18%)

STTK Shattuck Labs
$7.34 /

+0.06 (+0.82%)

SRRK Scholar Rock
$21.55 /

-0.53 (-2.40%)

SLDB Solid Biosciences
$1.49 /

-0.06 (-3.87%)

SEER Seer
$20.48 /

-0.03 (-0.15%)

RLAY Relay Therapeutics
$26.12 /

-1.57 (-5.67%)

RARE Ultragenyx
$71.15 /

-1.64 (-2.25%)

RAIN Rain Therapeutics
$12.05 /

-0.83 (-6.44%)

QSI Quantum-Si
$6.01 /

-0.28 (-4.45%)

QDEL Quidel
$124.62 /

-2.9099 (-2.28%)

PACB Pacific Biosciences
$14.46 /

-0.225 (-1.53%)

OMIC Singular Genomics
$8.19 /

-0.35 (-4.10%)

NVRO Nevro
$90.88 /

-0.27 (-0.30%)

NPCE NeuroPace
$11.55 /

+0.8 (+7.44%)

NOVT Novanta
$163.39 /

+0.07 (+0.04%)

MYGN Myriad Genetics
$26.17 /

-0.37 (-1.39%)

MRNS Marinus Pharmaceuticals
$10.85 /

-0.23 (-2.08%)

MOR MorphoSys
$8.99 /

-0.205 (-2.23%)

MOLN Molecular Partners
$27.00 /

+1.34 (+5.22%)

MODV ModivCare
$133.23 /

-1.36 (-1.01%)

JNJ Johnson & Johnson
$169.83 /

-1.43 (-0.83%)

JAZZ Jazz Pharmaceuticals
$144.87 /

-4.94 (-3.30%)

IVA Inventiva
$12.45 /

+ (+0.00%)

ITOS iTeos Therapeutics
$40.89 /

-0.64 (-1.54%)

ITCI Intra-Cellular
$39.77 /

-0.59 (-1.46%)

IART Integra LifeSciences
$67.56 /

+0.36 (+0.54%)

HZNP Horizon Therapeutics
$93.55 /

-2.38 (-2.48%)

GILD Gilead
$72.24 /

-0.12 (-0.17%)

ENDP Endo
$3.54 /

-0.165 (-4.45%)

DNA Ginkgo Bioworks
$6.26 /

-0.575 (-8.42%)

DAWN Day One Biopharmaceuticals
$15.39 /

+0.28 (+1.85%)

CRNX Crinetics
$24.65 /

-0.85 (-3.33%)

CI Cigna
$238.85 /

-1.1 (-0.46%)

CERN Cerner
$92.21 /

-0.04 (-0.04%)

BRKR Bruker
$73.60 /

+0.55 (+0.75%)

BNTX BioNTech
$221.16 /

+5.13 (+2.37%)

BHG Bright Health
$3.13 /

-0.085 (-2.65%)

BEAM Beam Therapeutics
$70.23 /

-5.49 (-7.25%)

BAX Baxter
$86.43 /

+0.08 (+0.09%)

AMRS Amyris
$5.28 /

+0.54 (+11.39%)

ALLO Allogene Therapeutics
$12.32 /

-0.545 (-4.24%)

ALKS Alkermes
$24.24 /

-0.76 (-3.04%)

ABBV AbbVie
$135.88 /

+0.24 (+0.18%)

ABBV AbbVie
$135.88 /

+0.24 (+0.18%)

01/12/22 BMO Capital
AbbVie price target raised to $153 from $134 at BMO Capital
01/11/22 Piper Sandler
AbbVie long range estimates need to come up, says Piper Sandler
01/05/22 Mizuho
Mizuho keeps AbbVie as top 2022 large cap pick, ups target
01/03/22 Piper Sandler
AbbVie price target raised to $160 from $129 at Piper Sandler
ALLO Allogene Therapeutics
$12.32 /

-0.545 (-4.24%)

01/10/22 Stifel
Allogene ASH update may be weighing on shares despite holds lifted, says Stifel
01/06/22 Wells Fargo
Wells Fargo downgrades Cellectis to Equal Weight, cuts price target to $16
01/03/22 Guggenheim
Allogene Therapeutics price target lowered to $35 from $40 at Guggenheim
01/03/22 B. Riley
iStar, Aspen Aerogels among B. Riley's top 25 stock picks for 2022
BAX Baxter
$86.43 /

+0.08 (+0.09%)

01/07/22 Morgan Stanley
Baxter upgraded to Overweight at Morgan Stanley after 'transformative' deal
01/07/22 Citi
Baxter resumed with a Buy at Citi
01/07/22 Morgan Stanley
Baxter upgraded to Overweight from Equal Weight at Morgan Stanley
01/04/22 Raymond James
Baxter price target raised to $99 from $93 at Raymond James
BHG Bright Health
$3.13 /

-0.085 (-2.65%)

01/10/22 Citi
Bright Health assumed with a Neutral at Citi
01/07/22 Barclays
Bright Health price target lowered to $5.50 from $9 at Barclays
12/17/21 Morgan Stanley
Bright Health downgraded to Underweight at Morgan Stanley
12/16/21 Morgan Stanley
Bright Health downgraded to Underweight from Equal Weight at Morgan Stanley
TWST Twist Bioscience
$62.99 /

-4.11 (-6.13%)

11/26/21 Benchmark
Recent deals highlight value in ImmunoPrecise shares, says Benchmark
11/23/21 Baird
Twist Bioscience price target lowered to $113 from $130 at Baird
10/14/21 Cowen
Twist Bioscience coverage transferred at Cowen
08/09/21 Baird
Twist Bioscience price target lowered to $130 from $140 at Baird
TXG 10x Genomics
$118.89 /

-2.99 (-2.45%)

10/14/21 Cowen
10x Genomics coverage transferred at Cowen
09/14/21
Fly Intel: Top five analyst downgrades
09/14/21 BofA
10x Genomics downgraded on 'incrementally more negative' tone at BofA
09/14/21 BofA
10x Genomics downgraded to Neutral from Buy at BofA
TDOC Teladoc
$81.83 /

-4.47 (-5.18%)

01/11/22 Piper Sandler
Teladoc price target lowered to $118 from $183 at Piper Sandler
12/02/21 Baird
Teladoc elevated to bullish Fresh Pick at Baird
12/01/21 Jefferies
Teladoc assumed with a Hold at Jefferies
11/23/21 Canaccord
Teladoc price target lowered to $160 from $188 at Canaccord
SRRK Scholar Rock
$21.55 /

-0.53 (-2.40%)

12/22/21 Jefferies
Scholar Rock downgraded to Hold on lack of catalysts at Jefferies
12/22/21 Jefferies
Scholar Rock downgraded to Hold from Buy at Jefferies
11/18/21 Piper Sandler
Scholar Rock initiated with an Overweight at Piper Sandler
06/11/21 BMO Capital
Scholar Rock coverage transferred at BMO Capital
SLDB Solid Biosciences
$1.49 /

-0.06 (-3.87%)

09/24/21 Chardan
Solid Biosciences price target lowered to $17 from $20 at Chardan
09/23/21 Piper Sandler
Piper Sandler 'cautiously optimistic' on Solid Biosciences after update
07/12/21 Piper Sandler
Solid Biosciences initiated with a Neutral at Piper Sandler
07/09/21 Chardan
Solid Biosciences coverage transferred at Chardan
RLAY Relay Therapeutics
$26.12 /

-1.57 (-5.67%)

01/03/22 Guggenheim
Relay Therapeutics price target lowered to $45 from $52 at Guggenheim
11/08/21 Jefferies
Tyra Biosciences cut to Hold at Jefferies on valuation, lack of catalysts
08/17/21 H.C. Wainwright
Relay Therapeutics price target lowered to $54 from $57 at H.C. Wainwright
07/21/21 BofA
BofA starts possible 'breakout star' Relay Therapeutics at Buy
QSI Quantum-Si
$6.01 /

-0.28 (-4.45%)

10/20/21 Canaccord
Quantum-Si initiated with a Buy at Canaccord
QDEL Quidel
$124.62 /

-2.9099 (-2.28%)

12/27/21 Raymond James
Quidel acquisition brings 'lower ceiling on growth,' says Raymond James
12/27/21 H.C. Wainwright
Ortho Clinical downgraded to Neutral from Buy at H.C. Wainwright
12/23/21 Evercore ISI
Evercore downgrades Ortho Clinical to In Line, doesn't see risk to deal closing
12/23/21
Fly Intel: Top five analyst downgrades
DAWN Day One Biopharmaceuticals
$15.39 /

+0.28 (+1.85%)

06/21/21 Cowen
Cowen starts Day One with Outperform on glioma potential
06/21/21 JPMorgan
Day One Biopharmaceuticals initiated with an Overweight at JPMorgan
06/21/21 Wedbush
Day One Biopharmaceuticals initiated with an Outperform at Wedbush
06/21/21 Wedbush
Day One Biopharmaceuticals initiated with an Outperform at Wedbush
CERN Cerner
$92.21 /

-0.04 (-0.04%)

01/06/22 Monness Crespi
Oracle selloff creates 'attractive buying opportunity,' says Monness Crespi
12/21/21 KeyBanc
Cerner downgraded to Sector Weight from Overweight at KeyBanc
12/21/21 Deutsche Bank
Oracle investors will come to appreciate Cerner deal, says Deutsche Bank
12/21/21 KeyBanc
KeyBanc downgrades Oracle, calls Cerner deal non-strategic
BRKR Bruker
$73.60 /

+0.55 (+0.75%)

10/14/21 Cowen
Bruker coverage transferred at Cowen
08/03/21 Wells Fargo
Bruker price target raised to $85 from $70 at Wells Fargo
08/03/21 Citi
Bruker price target raised to $85 from $75 at Citi
06/15/21 Cleveland Research
Bruker upgraded to Buy from Neutral at Cleveland Research
BNTX BioNTech
$221.16 /

+5.13 (+2.37%)

12/22/21 Kempen
BioNTech upgraded to Buy from Neutral at Kempen
12/21/21 H.C. Wainwright
BioNTech price target raised to $366 from $360 at H.C. Wainwright
12/16/21 Morgan Stanley
BioNTech initiated with an Equal Weight at Morgan Stanley
12/06/21 BofA
BioNTech price target raised to $349 from $341 at BofA
BEAM Beam Therapeutics
$70.23 /

-5.49 (-7.25%)

01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 Guggenheim
Guggenheim starts Beam Therapeutics with a Buy rating, $130 price target
01/05/22 Guggenheim
Beam Therapeutics initiated with a Buy at Guggenheim
10/19/21 SVB Leerink
Beam Therapeutics initiated with an Outperform at SVB Leerink
MOR MorphoSys
$8.99 /

-0.205 (-2.23%)

01/04/22 JPMorgan
MorphoSys price target lowered to EUR 40 from EUR 54 at JPMorgan
11/12/21 Morgan Stanley
MorphoSys price target raised to EUR 76 from EUR 75 at Morgan Stanley
09/27/21 Citi
MorphoSys downgraded to Neutral from Buy at Citi
09/13/21 Goldman Sachs
MorphoSys reinstated with a Neutral at Goldman Sachs
MOLN Molecular Partners
$27.00 /

+1.34 (+5.22%)

08/10/21 Credit Suisse
Molecular Partners price target lowered to CHF 18.50 at Credit Suisse
07/12/21 Cowen
Molecular Partners initiated with an Outperform at Cowen
07/12/21 RBC Capital
Molecular Partners price target lowered to CHF 26 from CHF 28 at RBC Capital
07/12/21 SVB Leerink
Molecular Partners assumed with an Outperform at SVB Leerink
MODV ModivCare
$133.23 /

-1.36 (-1.01%)

12/17/21 Deutsche Bank
ModivCare initiated with a Buy at Deutsche Bank
08/04/21 Barrington
ModivCare price target raised to $186 from $170 at Barrington
05/10/21 Barrington
ModivCare price target raised to $170 from $162 at Barrington
MYGN Myriad Genetics
$26.17 /

-0.37 (-1.39%)

10/14/21 Cowen
Myriad Genetics coverage transferred at Cowen
06/15/21
Fly Intel: Top five analyst initiations
06/15/21 Raymond James
Myriad Genetics initiated with a Market Perform at Raymond James
06/03/21 Goldman Sachs
Myriad Genetics initiated with a Sell at Goldman Sachs
CI Cigna
$238.85 /

-1.1 (-0.46%)

01/11/22 Bernstein
Cigna price target raised to $258 from $234 at Bernstein
01/06/22 Wells Fargo
Wells Fargo upgrades Cigna to Overweight, raises price target to $278
01/06/22 Wells Fargo
Cigna upgraded to Overweight from Equal Weight at Wells Fargo
01/05/22 Truist
Cigna price target raised to $275 from $270 at Truist
CRNX Crinetics
$24.65 /

-0.85 (-3.33%)

11/30/21 JMP Securities
Crinetics initiated with an Outperform at JMP Securities
11/23/21 Evercore ISI
Evercore starts 'rare endo treasure trove' Crinetics at Outperform
11/23/21 Evercore ISI
Crinetics initiated with an Outperform at Evercore ISI
06/18/21 JPMorgan
Crinetics upgraded to Overweight ahead of data at JPMorgan
DNA Ginkgo Bioworks
$6.26 /

-0.575 (-8.42%)

01/06/22 BTIG
BTIG starts Ginkgo Bioworks at Buy with $12 price target
01/06/22 BTIG
Ginkgo Bioworks initiated with a Buy at BTIG
11/29/21 Jefferies
Ginkgo Bioworks initiated with a Buy at Jefferies
10/20/21 Raymond James
Raymond James expects more equity-based payments for Ginkgo as milestones met
ENDP Endo
$3.54 /

-0.165 (-4.45%)

12/16/21 Barclays
Endo price target lowered to $5 from $7 at Barclays
11/05/21 Stifel
Endo's performance tempering 'noise' around litigation, says Stifel
08/31/21 Piper Sandler
Endo downgraded to Neutral at Piper Sandler following Vasostrict ruling loss
08/31/21 Piper Sandler
Endo downgraded to Neutral from Overweight at Piper Sandler
JNJ Johnson & Johnson
$169.83 /

-1.43 (-0.83%)

12/29/21 Credit Suisse
Credit Suisse reiterates Outperform on J&J as trends point to pharma upside
12/17/21
Fly Intel: Top five analyst initiations
12/17/21 Goldman Sachs
Goldman starts Johnson & Johnson at Neutral amid disruption risk
12/17/21 Goldman Sachs
Johnson & Johnson initiated with a Neutral at Goldman Sachs
GILD Gilead
$72.24 /

-0.12 (-0.17%)

01/06/22 Morgan Stanley
Gilead downgraded to Equal Weight from Overweight at Morgan Stanley
12/22/21 Piper Sandler
Piper says Gilead vial compatibility issue for lenacapavir 'minor and fixable'
12/22/21 Morgan Stanley
Gilead's injectable lenacapavir hold likely temporary, says Morgan Stanley
12/15/21 Jefferies
Bloomin', Callaway, Newell among five 'Franchise Picks' additions at Jefferies
HCAT Health Catalyst
$33.50 /

-1.1 (-3.18%)

12/01/21 Jefferies
Health Catalyst initiated with a Hold at Jefferies
10/14/21 BTIG
Health Catalyst initiated with a Buy at BTIG
08/10/21 RBC Capital
Health Catalyst price target raised to $66 from $60 at RBC Capital
08/06/21 Canaccord
Health Catalyst price target raised to $64 from $60 at Canaccord
HZNP Horizon Therapeutics
$93.55 /

-2.38 (-2.48%)

12/08/21
Fly Intel: Top five analyst initiations
12/08/21 Wells Fargo
Horizon Therapeutics initiated with an Overweight at Wells Fargo
11/18/21 Goldman Sachs
Horizon Therapeutics upgraded to Buy from Neutral at Goldman Sachs
10/12/21 Evercore ISI
Evercore starts Viridian at Outperform on thyroid eye disease opportunity
IART Integra LifeSciences
$67.56 /

+0.36 (+0.54%)

12/17/21 JPMorgan
Integra LifeSciences upgraded to Neutral on recent changes at JPMorgan
12/17/21 JPMorgan
Integra LifeSciences upgraded to Neutral from Underweight at JPMorgan
12/15/21 Citi
Integra LifeSciences price target lowered to $70 from $78 at Citi
10/28/21 Piper Sandler
Integra LifeSciences new CEO 'seems solid,' says Piper Sandler
JAZZ Jazz Pharmaceuticals
$144.87 /

-4.94 (-3.30%)

12/22/21 JPMorgan
Jazz Pharmaceuticals shares offer attractive entry point, says JPMorgan
12/20/21 SVB Leerink
Jazz Pharmaceuticals price target lowered to $200 from $230 at SVB Leerink
12/17/21 Needham
Jazz Pharmaceuticals price target lowered to $215 from $220 at Needham
11/18/21 Goldman Sachs
Jazz Pharmaceuticals reinstated with a Buy at Goldman Sachs
IVA Inventiva
$12.45 /

+ (+0.00%)

11/22/21 H.C. Wainwright
Inventiva price target raised to $42 from $40 at H.C. Wainwright
09/22/21 H.C. Wainwright
Inventiva price target raised to $40 from $38 at H.C. Wainwright
05/04/21 Roth Capital
Inventiva price target raised to EUR 55 from EUR 46 at Roth Capital
03/08/21
Fly Intel: Top five analyst downgrades
ITOS iTeos Therapeutics
$40.89 /

-0.64 (-1.54%)

12/16/21 Wedbush
iTeos Therapeutics added to 'Best Ideas List' at Wedbush
12/13/21 H.C. Wainwright
iTeos Therapeutics price target raised to $54 from $37 at H.C. Wainwright
11/11/21 Piper Sandler
iTeos Therapeutics price target lowered to $42 from $50 at Piper Sandler
06/14/21 Piper Sandler
iTeos deal 'addresses a number of needs all at once, says Piper Sandler
ITCI Intra-Cellular
$39.77 /

-0.59 (-1.46%)

12/21/21 RBC Capital
Intra-Cellular price target raised to $55 from $50 at RBC Capital
12/21/21 Jefferies
Intra-Cellular price target raised to $85 from $70 at Jefferies
12/20/21 Canaccord
Intra-Cellular price target raised to $88 from $81 at Canaccord
12/20/21 SVB Leerink
Intra-Cellular price target raised to $50 from $45 at SVB Leerink
MRNS Marinus Pharmaceuticals
$10.85 /

-0.23 (-2.08%)

08/18/21 Truist
Marinus Pharmaceuticals price target raised to $40 from $35 at Truist
03/10/21 H.C. Wainwright
Marinus Pharmaceuticals price target raised to $38 from $35 at H.C. Wainwright
NOVT Novanta
$163.39 /

+0.07 (+0.04%)

OMIC Singular Genomics
$8.19 /

-0.35 (-4.10%)

01/07/22 BofA
Singular Genomics upgraded to Buy from Neutral at BofA
01/07/22 BofA
Singular Genomics upgraded to Buy from Neutral at BofA
01/06/22 UBS
Singular Genomics price target lowered to $25 from $32 at UBS
10/14/21 Cowen
Singular Genomics coverage transferred at Cowen
PACB Pacific Biosciences
$14.46 /

-0.225 (-1.53%)

01/11/22 Piper Sandler
Pacific Biosciences has new competitor in Illumina, says Piper Sandler
01/05/22 Piper Sandler
Pacific Biosciences assumed with a Neutral at Piper Sandler
10/14/21 Cowen
Pacific Biosciences coverage transferred at Cowen
09/27/21 Canaccord
Pacific Biosciences initiated with a Buy at Canaccord
RARE Ultragenyx
$71.15 /

-1.64 (-2.25%)

01/05/22 Stifel
Stifel bullish on Ultragenyx, sees GTX-102 update as tailwind toward mid-22 data
11/03/21 Citi
Ultragenyx trading at 'significant discount to fair value,' says Citi
09/30/21 H.C. Wainwright
Ultragenyx initiated with a Buy at H.C. Wainwright
09/27/21 Piper Sandler
Piper 'incrementally positive' on Ultragenyx after clinical hold lift
RAIN Rain Therapeutics
$12.05 /

-0.83 (-6.44%)

01/03/22 Guggenheim
Rain Therapeutics price target lowered to $20 from $26 at Guggenheim
11/10/21 Piper Sandler
Rain Therapeutics price target raised to $26 from $25 at Piper Sandler
09/14/21 Goldman Sachs
Rain Therapeutics assumed with Neutral from Buy at Goldman Sachs
AMRS Amyris
$5.28 /

+0.54 (+11.39%)

11/09/21 Roth Capital
Amyris price target lowered to $15 from $22 at Roth Capital
10/14/21 Cowen
Amyris coverage transferred at Cowen
08/06/21 H.C. Wainwright
Amyris price target lowered to $30 from $35 at H.C. Wainwright
07/06/21 HSBC
Amyris is at 'tipping point on growth,' says HSBC
ALKS Alkermes
$24.24 /

-0.76 (-3.04%)

12/01/21 Citi
Alkermes initiated with a Neutral at Citi
11/09/21 Mizuho
Alkermes price target lowered to $33 from $36 at Mizuho
10/28/21 Mizuho
Alkermes shares have 25% upside after selloff, says Mizuho
10/28/21 H.C. Wainwright
Alkermes price target raised to $30 from $25 at H.C. Wainwright
NPCE NeuroPace
$11.55 /

+0.8 (+7.44%)

01/07/22 Morgan Stanley
NeuroPace cut to Underweight at Morgan Stanley on cloudy near-term outlook
01/07/22 Morgan Stanley
NeuroPace downgraded to Underweight from Equal Weight at Morgan Stanley
12/17/21 Baird
NeuroPace price target lowered to $20 from $23 at Baird
11/11/21 Morgan Stanley
Morgan Stanley downgrades NeuroPace on more uncertain recovery pace
NVRO Nevro
$90.88 /

-0.27 (-0.30%)

01/12/22 Canaccord
Nevro price target lowered to $97 from $118 at Canaccord
01/07/22 Morgan Stanley
Nevro downgraded to Equal Weight at Morgan Stanley on COVID and competition
01/07/22 Morgan Stanley
Nevro downgraded to Equal Weight from Overweight at Morgan Stanley
01/07/22 Piper Sandler
Nevro price target raised to $92 from $90 at Piper Sandler
SEER Seer
$20.48 /

-0.03 (-0.15%)

10/14/21 Cowen
Seer coverage transferred at Cowen
08/13/21 Morgan Stanley
Seer price target lowered to $50 from $55 at Morgan Stanley
STTK Shattuck Labs
$7.34 /

+0.06 (+0.82%)

04/14/21 Berenberg
Shattuck Labs initiated with a Buy at Berenberg
01/20/21 Citi
Shattuck Labs price target raised to $75 from $36 at Citi
TLIS Talis Biomedical
$3.24 /

-0.07 (-2.11%)

01/07/22 BofA
Talis Biomedical downgraded to Underperform from Neutral at BofA
09/27/21 JPMorgan
Talis Biomedical downgraded to Underweight from Neutral at JPMorgan
08/31/21 BTIG
Talis Biomedical downgraded to Neutral at BTIG following CEO departure
08/31/21 BTIG
Talis Biomedical downgraded to Neutral from Buy at BTIG
TXG 10x Genomics
$118.89 /

-2.99 (-2.45%)

TWST Twist Bioscience
$62.99 /

-4.11 (-6.13%)

TLIS Talis Biomedical
$3.24 /

-0.07 (-2.11%)

TDOC Teladoc
$81.83 /

-4.47 (-5.18%)

STTK Shattuck Labs
$7.34 /

+0.06 (+0.82%)

SRRK Scholar Rock
$21.55 /

-0.53 (-2.40%)

SLDB Solid Biosciences
$1.49 /

-0.06 (-3.87%)

SEER Seer
$20.48 /

-0.03 (-0.15%)

RLAY Relay Therapeutics
$26.12 /

-1.57 (-5.67%)

RARE Ultragenyx
$71.15 /

-1.64 (-2.25%)

RAIN Rain Therapeutics
$12.05 /

-0.83 (-6.44%)

QSI Quantum-Si
$6.01 /

-0.28 (-4.45%)

QDEL Quidel
$124.62 /

-2.9099 (-2.28%)

PACB Pacific Biosciences
$14.46 /

-0.225 (-1.53%)

OMIC Singular Genomics
$8.19 /

-0.35 (-4.10%)

NVRO Nevro
$90.88 /

-0.27 (-0.30%)

NPCE NeuroPace
$11.55 /

+0.8 (+7.44%)

NOVT Novanta
$163.39 /

+0.07 (+0.04%)

MYGN Myriad Genetics
$26.17 /

-0.37 (-1.39%)

MRNS Marinus Pharmaceuticals
$10.85 /

-0.23 (-2.08%)

MOR MorphoSys
$8.99 /

-0.205 (-2.23%)

MODV ModivCare
$133.23 /

-1.36 (-1.01%)

JNJ Johnson & Johnson
$169.83 /

-1.43 (-0.83%)

JAZZ Jazz Pharmaceuticals
$144.87 /

-4.94 (-3.30%)

ITOS iTeos Therapeutics
$40.89 /

-0.64 (-1.54%)

ITCI Intra-Cellular
$39.77 /

-0.59 (-1.46%)

IART Integra LifeSciences
$67.56 /

+0.36 (+0.54%)

HZNP Horizon Therapeutics
$93.55 /

-2.38 (-2.48%)

HCAT Health Catalyst
$33.50 /

-1.1 (-3.18%)

GILD Gilead
$72.24 /

-0.12 (-0.17%)

ENDP Endo
$3.54 /

-0.165 (-4.45%)

DNA Ginkgo Bioworks
$6.26 /

-0.575 (-8.42%)

DAWN Day One Biopharmaceuticals
$15.39 /

+0.28 (+1.85%)

CRNX Crinetics
$24.65 /

-0.85 (-3.33%)

CI Cigna
$238.85 /

-1.1 (-0.46%)

CERN Cerner
$92.21 /

-0.04 (-0.04%)

BRKR Bruker
$73.60 /

+0.55 (+0.75%)

BNTX BioNTech
$221.16 /

+5.13 (+2.37%)

BHG Bright Health
$3.13 /

-0.085 (-2.65%)

BEAM Beam Therapeutics
$70.23 /

-5.49 (-7.25%)

BAX Baxter
$86.43 /

+0.08 (+0.09%)

AMRS Amyris
$5.28 /

+0.54 (+11.39%)

ALLO Allogene Therapeutics
$12.32 /

-0.545 (-4.24%)

ALKS Alkermes
$24.24 /

-0.76 (-3.04%)

ABBV AbbVie
$135.88 /

+0.24 (+0.18%)

  • 05
    Jan
  • 21
    Oct
  • 13
    Oct
  • 11
    Aug
  • 24
    Jun
  • 16
    Jun
  • 27
    May
  • 27
    May
  • 23
    Apr
  • 22
    Apr
  • 09
    Apr
  • 08
    Apr
  • 19
    Mar
  • 12
    Feb
  • 28
    Jan
SEER Seer
$20.48 /

-0.03 (-0.15%)

QDEL Quidel
$124.62 /

-2.9099 (-2.28%)

NPCE NeuroPace
$11.55 /

+0.8 (+7.44%)

MYGN Myriad Genetics
$26.17 /

-0.37 (-1.39%)

JNJ Johnson & Johnson
$169.83 /

-1.43 (-0.83%)

HZNP Horizon Therapeutics
$93.55 /

-2.38 (-2.48%)

GILD Gilead
$72.24 /

-0.12 (-0.17%)

ENDP Endo
$3.54 /

-0.165 (-4.45%)

DNA Ginkgo Bioworks
$6.26 /

-0.575 (-8.42%)

CI Cigna
$238.85 /

-1.1 (-0.46%)

CERN Cerner
$92.21 /

-0.04 (-0.04%)

BNTX BioNTech
$221.16 /

+5.13 (+2.37%)

BAX Baxter
$86.43 /

+0.08 (+0.09%)

AMRS Amyris
$5.28 /

+0.54 (+11.39%)

ABBV AbbVie
$135.88 /

+0.24 (+0.18%)

TWST Twist Bioscience
$62.99 /

-4.11 (-6.13%)

TDOC Teladoc
$81.83 /

-4.47 (-5.18%)

SEER Seer
$20.48 /

-0.03 (-0.15%)

RLAY Relay Therapeutics
$26.12 /

-1.57 (-5.67%)

RARE Ultragenyx
$71.15 /

-1.64 (-2.25%)

QDEL Quidel
$124.62 /

-2.9099 (-2.28%)

PACB Pacific Biosciences
$14.46 /

-0.225 (-1.53%)

NVRO Nevro
$90.88 /

-0.27 (-0.30%)

MOR MorphoSys
$8.99 /

-0.205 (-2.23%)

JNJ Johnson & Johnson
$169.83 /

-1.43 (-0.83%)

JAZZ Jazz Pharmaceuticals
$144.87 /

-4.94 (-3.30%)

ITCI Intra-Cellular
$39.77 /

-0.59 (-1.46%)

IART Integra LifeSciences
$67.56 /

+0.36 (+0.54%)

HZNP Horizon Therapeutics
$93.55 /

-2.38 (-2.48%)

HCAT Health Catalyst
$33.50 /

-1.1 (-3.18%)

GILD Gilead
$72.24 /

-0.12 (-0.17%)

ENDP Endo
$3.54 /

-0.165 (-4.45%)

DNA Ginkgo Bioworks
$6.26 /

-0.575 (-8.42%)

CRNX Crinetics
$24.65 /

-0.85 (-3.33%)

CI Cigna
$238.85 /

-1.1 (-0.46%)

CERN Cerner
$92.21 /

-0.04 (-0.04%)

BRKR Bruker
$73.60 /

+0.55 (+0.75%)

BNTX BioNTech
$221.16 /

+5.13 (+2.37%)

BHG Bright Health
$3.13 /

-0.085 (-2.65%)

BEAM Beam Therapeutics
$70.23 /

-5.49 (-7.25%)

BAX Baxter
$86.43 /

+0.08 (+0.09%)

AMRS Amyris
$5.28 /

+0.54 (+11.39%)

ALLO Allogene Therapeutics
$12.32 /

-0.545 (-4.24%)

ALKS Alkermes
$24.24 /

-0.76 (-3.04%)

ABBV AbbVie
$135.88 /

+0.24 (+0.18%)

TDOC Teladoc
$81.83 /

-4.47 (-5.18%)

STTK Shattuck Labs
$7.34 /

+0.06 (+0.82%)

PACB Pacific Biosciences
$14.46 /

-0.225 (-1.53%)

JNJ Johnson & Johnson
$169.83 /

-1.43 (-0.83%)

ITOS iTeos Therapeutics
$40.89 /

-0.64 (-1.54%)

GILD Gilead
$72.24 /

-0.12 (-0.17%)

ENDP Endo
$3.54 /

-0.165 (-4.45%)

DNA Ginkgo Bioworks
$6.26 /

-0.575 (-8.42%)

CRNX Crinetics
$24.65 /

-0.85 (-3.33%)

CI Cigna
$238.85 /

-1.1 (-0.46%)

CERN Cerner
$92.21 /

-0.04 (-0.04%)

BNTX BioNTech
$221.16 /

+5.13 (+2.37%)

BHG Bright Health
$3.13 /

-0.085 (-2.65%)

BAX Baxter
$86.43 /

+0.08 (+0.09%)

AMRS Amyris
$5.28 /

+0.54 (+11.39%)

ALLO Allogene Therapeutics
$12.32 /

-0.545 (-4.24%)

ABBV AbbVie
$135.88 /

+0.24 (+0.18%)

Recommendations
AbbVie price target raised to $153 from $134 at BMO Capital » 06:59
01/12/22
01/12
06:59
01/12/22
06:59
ABBV

AbbVie

$137.03 /

+0.64 (+0.47%)

BMO Capital analyst Gary…

BMO Capital analyst Gary Nachman raised the firm's price target on AbbVie to $153 from $134 and keeps an Outperform rating on the shares. The company's update at JPMorgan conference reaffirmed its confidence in the long-term growth prospects post the Humira loss of exclusivity next year with maintained 2025 guidance for combined Skyrizi/Rinvoq, the analyst tells investors in a research note. Nachman further cites AbbVie's indication that its Immunology franchise is expected to ultimately surpass Humira's peak.

ShowHide Related Items >><<
ABBV AbbVie
$137.03 /

+0.64 (+0.47%)

ABBV AbbVie
$137.03 /

+0.64 (+0.47%)

01/11/22 Piper Sandler
AbbVie long range estimates need to come up, says Piper Sandler
01/05/22 Mizuho
Mizuho keeps AbbVie as top 2022 large cap pick, ups target
01/03/22 Piper Sandler
AbbVie price target raised to $160 from $129 at Piper Sandler
12/17/21 Goldman Sachs
AbbVie initiated with a Neutral at Goldman Sachs
ABBV AbbVie
$137.03 /

+0.64 (+0.47%)

ABBV AbbVie
$137.03 /

+0.64 (+0.47%)

ABBV AbbVie
$137.03 /

+0.64 (+0.47%)

ABBV AbbVie
$137.03 /

+0.64 (+0.47%)

Conference/Events
JPMorgan to hold a virtual conference » 04:55
01/12/22
01/12
04:55
01/12/22
04:55
ABBV

AbbVie

$137.03 /

+0.64 (+0.47%)

, ALLO

Allogene Therapeutics

$12.88 /

+0.68 (+5.58%)

, BAX

Baxter

$86.35 /

+0.02 (+0.02%)

, BHG

Bright Health

$3.21 /

+0.12 (+3.88%)

, TWST

Twist Bioscience

$67.10 /

+0.57 (+0.86%)

, TXG

10x Genomics

$121.88 /

-5.76 (-4.51%)

, TDOC

Teladoc

$86.25 /

+4.07 (+4.95%)

, SRRK

Scholar Rock

$22.04 /

+0.23 (+1.05%)

, SLDB

Solid Biosciences

$1.55 /

+0.02 (+1.31%)

, RLAY

Relay Therapeutics

$27.69 /

+0.76 (+2.82%)

, QSI

Quantum-Si

$6.30 /

+0.425 (+7.23%)

, QDEL

Quidel

$127.53 /

-3 (-2.30%)

, DAWN

Day One Biopharmaceuticals

$15.11 /

+0.62 (+4.28%)

, CERN

Cerner

$92.25 /

-0.1 (-0.11%)

, BRKR

Bruker

$73.05 /

-0.56 (-0.76%)

, BNTX

BioNTech

$215.88 /

-14.32 (-6.22%)

, BEAM

Beam Therapeutics

$75.72 /

+7.3 (+10.67%)

, MOR

MorphoSys

$9.19 /

+0.03 (+0.33%)

, MOLN

Molecular Partners

$25.61 /

+4.37 (+20.57%)

, MODV

ModivCare

$134.57 /

+2.57 (+1.95%)

, MYGN

Myriad Genetics

$26.57 /

+0.85 (+3.30%)

, CI

Cigna

$239.95 /

+6.37 (+2.73%)

, CRNX

Crinetics

$25.49 /

+0.62 (+2.49%)

, DNA

Ginkgo Bioworks

$6.83 /

+0.115 (+1.71%)

, ENDP

Endo

$3.71 /

-0.055 (-1.46%)

, JNJ

Johnson & Johnson

$171.26 /

-1.835 (-1.06%)

, GILD

Gilead

$72.36 /

+0.28 (+0.39%)

, HCAT

Health Catalyst

$34.60 /

+1.17 (+3.50%)

, HZNP

Horizon Therapeutics

$96.04 /

+1.06 (+1.12%)

, IART

Integra LifeSciences

$67.20 /

+0.33 (+0.49%)

, JAZZ

Jazz Pharmaceuticals

$149.80 /

+2.73 (+1.86%)

, IVA

Inventiva

$12.45 /

+0.05 (+0.40%)

, ITOS

iTeos Therapeutics

$41.64 /

-0.18 (-0.43%)

, ITCI

Intra-Cellular

$40.36 /

-0.66 (-1.61%)

, MRNS

Marinus Pharmaceuticals

$11.07 /

-0.27 (-2.38%)

, NOVT

Novanta

$164.54 /

+5.7 (+3.59%)

, OMIC

Singular Genomics

$8.54 /

-0.74 (-7.97%)

, PACB

Pacific Biosciences

$14.70 /

-1.89 (-11.39%)

, RARE

Ultragenyx

$72.82 /

-0.3 (-0.41%)

, RAIN

Rain Therapeutics

$12.89 /

+1.39 (+12.09%)

, AMRS

Amyris

$4.74 /

+0.235 (+5.22%)

, ALKS

Alkermes

$25.01 /

+0.735 (+3.03%)

, NPCE

NeuroPace

$10.80 /

+0.8 (+8.00%)

, NVRO

Nevro

$91.32 /

+5.615 (+6.55%)

, SEER

Seer

$20.51 /

+1.535 (+8.09%)

, STTK

Shattuck Labs

$7.31 /

-0.06 (-0.81%)

, TLIS

Talis Biomedical

$3.30 /

+0.11 (+3.45%)

40th Annual Healthcare…

40th Annual Healthcare Virtual Conference to be held on January 10-13.Webcast Link

ShowHide Related Items >><<
TXG 10x Genomics
$121.88 /

-5.76 (-4.51%)

TWST Twist Bioscience
$67.10 /

+0.57 (+0.86%)

TLIS Talis Biomedical
$3.30 /

+0.11 (+3.45%)

TDOC Teladoc
$86.25 /

+4.07 (+4.95%)

STTK Shattuck Labs
$7.31 /

-0.06 (-0.81%)

SRRK Scholar Rock
$22.04 /

+0.23 (+1.05%)

SLDB Solid Biosciences
$1.55 /

+0.02 (+1.31%)

SEER Seer
$20.51 /

+1.535 (+8.09%)

RLAY Relay Therapeutics
$27.69 /

+0.76 (+2.82%)

RARE Ultragenyx
$72.82 /

-0.3 (-0.41%)

RAIN Rain Therapeutics
$12.89 /

+1.39 (+12.09%)

QSI Quantum-Si
$6.30 /

+0.425 (+7.23%)

QDEL Quidel
$127.53 /

-3 (-2.30%)

PACB Pacific Biosciences
$14.70 /

-1.89 (-11.39%)

OMIC Singular Genomics
$8.54 /

-0.74 (-7.97%)

NVRO Nevro
$91.32 /

+5.615 (+6.55%)

NPCE NeuroPace
$10.80 /

+0.8 (+8.00%)

NOVT Novanta
$164.54 /

+5.7 (+3.59%)

MYGN Myriad Genetics
$26.57 /

+0.85 (+3.30%)

MRNS Marinus Pharmaceuticals
$11.07 /

-0.27 (-2.38%)

MOR MorphoSys
$9.19 /

+0.03 (+0.33%)

MOLN Molecular Partners
$25.61 /

+4.37 (+20.57%)

MODV ModivCare
$134.57 /

+2.57 (+1.95%)

JNJ Johnson & Johnson
$171.26 /

-1.835 (-1.06%)

JAZZ Jazz Pharmaceuticals
$149.80 /

+2.73 (+1.86%)

IVA Inventiva
$12.45 /

+0.05 (+0.40%)

ITOS iTeos Therapeutics
$41.64 /

-0.18 (-0.43%)

ITCI Intra-Cellular
$40.36 /

-0.66 (-1.61%)

IART Integra LifeSciences
$67.20 /

+0.33 (+0.49%)

HZNP Horizon Therapeutics
$96.04 /

+1.06 (+1.12%)

GILD Gilead
$72.36 /

+0.28 (+0.39%)

ENDP Endo
$3.71 /

-0.055 (-1.46%)

DNA Ginkgo Bioworks
$6.83 /

+0.115 (+1.71%)

DAWN Day One Biopharmaceuticals
$15.11 /

+0.62 (+4.28%)

CRNX Crinetics
$25.49 /

+0.62 (+2.49%)

CI Cigna
$239.95 /

+6.37 (+2.73%)

CERN Cerner
$92.25 /

-0.1 (-0.11%)

BRKR Bruker
$73.05 /

-0.56 (-0.76%)

BNTX BioNTech
$215.88 /

-14.32 (-6.22%)

BHG Bright Health
$3.21 /

+0.12 (+3.88%)

BEAM Beam Therapeutics
$75.72 /

+7.3 (+10.67%)

BAX Baxter
$86.35 /

+0.02 (+0.02%)

AMRS Amyris
$4.74 /

+0.235 (+5.22%)

ALLO Allogene Therapeutics
$12.88 /

+0.68 (+5.58%)

ALKS Alkermes
$25.01 /

+0.735 (+3.03%)

ABBV AbbVie
$137.03 /

+0.64 (+0.47%)

ABBV AbbVie
$137.03 /

+0.64 (+0.47%)

01/11/22 Piper Sandler
AbbVie long range estimates need to come up, says Piper Sandler
01/05/22 Mizuho
Mizuho keeps AbbVie as top 2022 large cap pick, ups target
01/03/22 Piper Sandler
AbbVie price target raised to $160 from $129 at Piper Sandler
12/17/21 Goldman Sachs
AbbVie initiated with a Neutral at Goldman Sachs
ALLO Allogene Therapeutics
$12.88 /

+0.68 (+5.58%)

01/10/22 Stifel
Allogene ASH update may be weighing on shares despite holds lifted, says Stifel
01/06/22 Wells Fargo
Wells Fargo downgrades Cellectis to Equal Weight, cuts price target to $16
01/03/22 Guggenheim
Allogene Therapeutics price target lowered to $35 from $40 at Guggenheim
01/03/22 B. Riley
iStar, Aspen Aerogels among B. Riley's top 25 stock picks for 2022
BAX Baxter
$86.35 /

+0.02 (+0.02%)

01/07/22 Morgan Stanley
Baxter upgraded to Overweight at Morgan Stanley after 'transformative' deal
01/07/22 Citi
Baxter resumed with a Buy at Citi
01/07/22 Morgan Stanley
Baxter upgraded to Overweight from Equal Weight at Morgan Stanley
01/04/22 Raymond James
Baxter price target raised to $99 from $93 at Raymond James
BHG Bright Health
$3.21 /

+0.12 (+3.88%)

01/10/22 Citi
Bright Health assumed with a Neutral at Citi
01/07/22 Barclays
Bright Health price target lowered to $5.50 from $9 at Barclays
12/17/21 Morgan Stanley
Bright Health downgraded to Underweight at Morgan Stanley
12/16/21 Morgan Stanley
Bright Health downgraded to Underweight from Equal Weight at Morgan Stanley
TWST Twist Bioscience
$67.10 /

+0.57 (+0.86%)

11/26/21 Benchmark
Recent deals highlight value in ImmunoPrecise shares, says Benchmark
11/23/21 Baird
Twist Bioscience price target lowered to $113 from $130 at Baird
10/14/21 Cowen
Twist Bioscience coverage transferred at Cowen
08/09/21 Baird
Twist Bioscience price target lowered to $130 from $140 at Baird
TXG 10x Genomics
$121.88 /

-5.76 (-4.51%)

10/14/21 Cowen
10x Genomics coverage transferred at Cowen
09/14/21
Fly Intel: Top five analyst downgrades
09/14/21 BofA
10x Genomics downgraded on 'incrementally more negative' tone at BofA
09/14/21 BofA
10x Genomics downgraded to Neutral from Buy at BofA
TDOC Teladoc
$86.25 /

+4.07 (+4.95%)

01/11/22 Piper Sandler
Teladoc price target lowered to $118 from $183 at Piper Sandler
12/02/21 Baird
Teladoc elevated to bullish Fresh Pick at Baird
12/01/21 Jefferies
Teladoc assumed with a Hold at Jefferies
11/23/21 Canaccord
Teladoc price target lowered to $160 from $188 at Canaccord
SRRK Scholar Rock
$22.04 /

+0.23 (+1.05%)

12/22/21 Jefferies
Scholar Rock downgraded to Hold on lack of catalysts at Jefferies
12/22/21 Jefferies
Scholar Rock downgraded to Hold from Buy at Jefferies
11/18/21 Piper Sandler
Scholar Rock initiated with an Overweight at Piper Sandler
06/11/21 BMO Capital
Scholar Rock coverage transferred at BMO Capital
SLDB Solid Biosciences
$1.55 /

+0.02 (+1.31%)

09/24/21 Chardan
Solid Biosciences price target lowered to $17 from $20 at Chardan
09/23/21 Piper Sandler
Piper Sandler 'cautiously optimistic' on Solid Biosciences after update
07/12/21 Piper Sandler
Solid Biosciences initiated with a Neutral at Piper Sandler
07/09/21 Chardan
Solid Biosciences coverage transferred at Chardan
RLAY Relay Therapeutics
$27.69 /

+0.76 (+2.82%)

01/03/22 Guggenheim
Relay Therapeutics price target lowered to $45 from $52 at Guggenheim
11/08/21 Jefferies
Tyra Biosciences cut to Hold at Jefferies on valuation, lack of catalysts
08/17/21 H.C. Wainwright
Relay Therapeutics price target lowered to $54 from $57 at H.C. Wainwright
07/21/21 BofA
BofA starts possible 'breakout star' Relay Therapeutics at Buy
QSI Quantum-Si
$6.30 /

+0.425 (+7.23%)

10/20/21 Canaccord
Quantum-Si initiated with a Buy at Canaccord
QDEL Quidel
$127.53 /

-3 (-2.30%)

12/27/21 Raymond James
Quidel acquisition brings 'lower ceiling on growth,' says Raymond James
12/27/21 H.C. Wainwright
Ortho Clinical downgraded to Neutral from Buy at H.C. Wainwright
12/23/21 Evercore ISI
Evercore downgrades Ortho Clinical to In Line, doesn't see risk to deal closing
12/23/21
Fly Intel: Top five analyst downgrades
DAWN Day One Biopharmaceuticals
$15.11 /

+0.62 (+4.28%)

06/21/21 Cowen
Cowen starts Day One with Outperform on glioma potential
06/21/21 JPMorgan
Day One Biopharmaceuticals initiated with an Overweight at JPMorgan
06/21/21 Wedbush
Day One Biopharmaceuticals initiated with an Outperform at Wedbush
06/21/21 Wedbush
Day One Biopharmaceuticals initiated with an Outperform at Wedbush
CERN Cerner
$92.25 /

-0.1 (-0.11%)

01/06/22 Monness Crespi
Oracle selloff creates 'attractive buying opportunity,' says Monness Crespi
12/21/21 KeyBanc
Cerner downgraded to Sector Weight from Overweight at KeyBanc
12/21/21 Deutsche Bank
Oracle investors will come to appreciate Cerner deal, says Deutsche Bank
12/21/21 KeyBanc
KeyBanc downgrades Oracle, calls Cerner deal non-strategic
BRKR Bruker
$73.05 /

-0.56 (-0.76%)

10/14/21 Cowen
Bruker coverage transferred at Cowen
08/03/21 Wells Fargo
Bruker price target raised to $85 from $70 at Wells Fargo
08/03/21 Citi
Bruker price target raised to $85 from $75 at Citi
06/15/21 Cleveland Research
Bruker upgraded to Buy from Neutral at Cleveland Research
BNTX BioNTech
$215.88 /

-14.32 (-6.22%)

12/22/21 Kempen
BioNTech upgraded to Buy from Neutral at Kempen
12/21/21 H.C. Wainwright
BioNTech price target raised to $366 from $360 at H.C. Wainwright
12/16/21 Morgan Stanley
BioNTech initiated with an Equal Weight at Morgan Stanley
12/06/21 BofA
BioNTech price target raised to $349 from $341 at BofA
BEAM Beam Therapeutics
$75.72 /

+7.3 (+10.67%)

01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 Guggenheim
Guggenheim starts Beam Therapeutics with a Buy rating, $130 price target
01/05/22 Guggenheim
Beam Therapeutics initiated with a Buy at Guggenheim
10/19/21 SVB Leerink
Beam Therapeutics initiated with an Outperform at SVB Leerink
MOR MorphoSys
$9.19 /

+0.03 (+0.33%)

01/04/22 JPMorgan
MorphoSys price target lowered to EUR 40 from EUR 54 at JPMorgan
11/12/21 Morgan Stanley
MorphoSys price target raised to EUR 76 from EUR 75 at Morgan Stanley
09/27/21 Citi
MorphoSys downgraded to Neutral from Buy at Citi
09/13/21 Goldman Sachs
MorphoSys reinstated with a Neutral at Goldman Sachs
MOLN Molecular Partners
$25.61 /

+4.37 (+20.57%)

08/10/21 Credit Suisse
Molecular Partners price target lowered to CHF 18.50 at Credit Suisse
07/12/21 Cowen
Molecular Partners initiated with an Outperform at Cowen
07/12/21 RBC Capital
Molecular Partners price target lowered to CHF 26 from CHF 28 at RBC Capital
07/12/21 SVB Leerink
Molecular Partners assumed with an Outperform at SVB Leerink
MODV ModivCare
$134.57 /

+2.57 (+1.95%)

12/17/21 Deutsche Bank
ModivCare initiated with a Buy at Deutsche Bank
08/04/21 Barrington
ModivCare price target raised to $186 from $170 at Barrington
05/10/21 Barrington
ModivCare price target raised to $170 from $162 at Barrington
MYGN Myriad Genetics
$26.57 /

+0.85 (+3.30%)

10/14/21 Cowen
Myriad Genetics coverage transferred at Cowen
06/15/21
Fly Intel: Top five analyst initiations
06/15/21 Raymond James
Myriad Genetics initiated with a Market Perform at Raymond James
06/03/21 Goldman Sachs
Myriad Genetics initiated with a Sell at Goldman Sachs
CI Cigna
$239.95 /

+6.37 (+2.73%)

01/11/22 Bernstein
Cigna price target raised to $258 from $234 at Bernstein
01/06/22 Wells Fargo
Wells Fargo upgrades Cigna to Overweight, raises price target to $278
01/06/22 Wells Fargo
Cigna upgraded to Overweight from Equal Weight at Wells Fargo
01/05/22 Truist
Cigna price target raised to $275 from $270 at Truist
CRNX Crinetics
$25.49 /

+0.62 (+2.49%)

11/30/21 JMP Securities
Crinetics initiated with an Outperform at JMP Securities
11/23/21 Evercore ISI
Evercore starts 'rare endo treasure trove' Crinetics at Outperform
11/23/21 Evercore ISI
Crinetics initiated with an Outperform at Evercore ISI
06/18/21 JPMorgan
Crinetics upgraded to Overweight ahead of data at JPMorgan
DNA Ginkgo Bioworks
$6.83 /

+0.115 (+1.71%)

01/06/22 BTIG
BTIG starts Ginkgo Bioworks at Buy with $12 price target
01/06/22 BTIG
Ginkgo Bioworks initiated with a Buy at BTIG
11/29/21 Jefferies
Ginkgo Bioworks initiated with a Buy at Jefferies
10/20/21 Raymond James
Raymond James expects more equity-based payments for Ginkgo as milestones met
ENDP Endo
$3.71 /

-0.055 (-1.46%)

12/16/21 Barclays
Endo price target lowered to $5 from $7 at Barclays
11/05/21 Stifel
Endo's performance tempering 'noise' around litigation, says Stifel
08/31/21 Piper Sandler
Endo downgraded to Neutral at Piper Sandler following Vasostrict ruling loss
08/31/21 Piper Sandler
Endo downgraded to Neutral from Overweight at Piper Sandler
JNJ Johnson & Johnson
$171.26 /

-1.835 (-1.06%)

12/29/21 Credit Suisse
Credit Suisse reiterates Outperform on J&J as trends point to pharma upside
12/17/21
Fly Intel: Top five analyst initiations
12/17/21 Goldman Sachs
Goldman starts Johnson & Johnson at Neutral amid disruption risk
12/17/21 Goldman Sachs
Johnson & Johnson initiated with a Neutral at Goldman Sachs
GILD Gilead
$72.36 /

+0.28 (+0.39%)

01/06/22 Morgan Stanley
Gilead downgraded to Equal Weight from Overweight at Morgan Stanley
12/22/21 Piper Sandler
Piper says Gilead vial compatibility issue for lenacapavir 'minor and fixable'
12/22/21 Morgan Stanley
Gilead's injectable lenacapavir hold likely temporary, says Morgan Stanley
12/15/21 Jefferies
Bloomin', Callaway, Newell among five 'Franchise Picks' additions at Jefferies
HCAT Health Catalyst
$34.60 /

+1.17 (+3.50%)

12/01/21 Jefferies
Health Catalyst initiated with a Hold at Jefferies
10/14/21 BTIG
Health Catalyst initiated with a Buy at BTIG
08/10/21 RBC Capital
Health Catalyst price target raised to $66 from $60 at RBC Capital
08/06/21 Canaccord
Health Catalyst price target raised to $64 from $60 at Canaccord
HZNP Horizon Therapeutics
$96.04 /

+1.06 (+1.12%)

12/08/21
Fly Intel: Top five analyst initiations
12/08/21 Wells Fargo
Horizon Therapeutics initiated with an Overweight at Wells Fargo
11/18/21 Goldman Sachs
Horizon Therapeutics upgraded to Buy from Neutral at Goldman Sachs
10/12/21 Evercore ISI
Evercore starts Viridian at Outperform on thyroid eye disease opportunity
IART Integra LifeSciences
$67.20 /

+0.33 (+0.49%)

12/17/21 JPMorgan
Integra LifeSciences upgraded to Neutral on recent changes at JPMorgan
12/17/21 JPMorgan
Integra LifeSciences upgraded to Neutral from Underweight at JPMorgan
12/15/21 Citi
Integra LifeSciences price target lowered to $70 from $78 at Citi
10/28/21 Piper Sandler
Integra LifeSciences new CEO 'seems solid,' says Piper Sandler
JAZZ Jazz Pharmaceuticals
$149.80 /

+2.73 (+1.86%)

12/22/21 JPMorgan
Jazz Pharmaceuticals shares offer attractive entry point, says JPMorgan
12/20/21 SVB Leerink
Jazz Pharmaceuticals price target lowered to $200 from $230 at SVB Leerink
12/17/21 Needham
Jazz Pharmaceuticals price target lowered to $215 from $220 at Needham
11/18/21 Goldman Sachs
Jazz Pharmaceuticals reinstated with a Buy at Goldman Sachs
IVA Inventiva
$12.45 /

+0.05 (+0.40%)

11/22/21 H.C. Wainwright
Inventiva price target raised to $42 from $40 at H.C. Wainwright
09/22/21 H.C. Wainwright
Inventiva price target raised to $40 from $38 at H.C. Wainwright
05/04/21 Roth Capital
Inventiva price target raised to EUR 55 from EUR 46 at Roth Capital
03/08/21
Fly Intel: Top five analyst downgrades
ITOS iTeos Therapeutics
$41.64 /

-0.18 (-0.43%)

12/16/21 Wedbush
iTeos Therapeutics added to 'Best Ideas List' at Wedbush
12/13/21 H.C. Wainwright
iTeos Therapeutics price target raised to $54 from $37 at H.C. Wainwright
11/11/21 Piper Sandler
iTeos Therapeutics price target lowered to $42 from $50 at Piper Sandler
06/14/21 Piper Sandler
iTeos deal 'addresses a number of needs all at once, says Piper Sandler
ITCI Intra-Cellular
$40.36 /

-0.66 (-1.61%)

12/21/21 RBC Capital
Intra-Cellular price target raised to $55 from $50 at RBC Capital
12/21/21 Jefferies
Intra-Cellular price target raised to $85 from $70 at Jefferies
12/20/21 Canaccord
Intra-Cellular price target raised to $88 from $81 at Canaccord
12/20/21 SVB Leerink
Intra-Cellular price target raised to $50 from $45 at SVB Leerink
MRNS Marinus Pharmaceuticals
$11.07 /

-0.27 (-2.38%)

08/18/21 Truist
Marinus Pharmaceuticals price target raised to $40 from $35 at Truist
03/10/21 H.C. Wainwright
Marinus Pharmaceuticals price target raised to $38 from $35 at H.C. Wainwright
NOVT Novanta
$164.54 /

+5.7 (+3.59%)

OMIC Singular Genomics
$8.54 /

-0.74 (-7.97%)

01/07/22 BofA
Singular Genomics upgraded to Buy from Neutral at BofA
01/07/22 BofA
Singular Genomics upgraded to Buy from Neutral at BofA
01/06/22 UBS
Singular Genomics price target lowered to $25 from $32 at UBS
10/14/21 Cowen
Singular Genomics coverage transferred at Cowen
PACB Pacific Biosciences
$14.70 /

-1.89 (-11.39%)

01/11/22 Piper Sandler
Pacific Biosciences has new competitor in Illumina, says Piper Sandler
01/05/22 Piper Sandler
Pacific Biosciences assumed with a Neutral at Piper Sandler
10/14/21 Cowen
Pacific Biosciences coverage transferred at Cowen
09/27/21 Canaccord
Pacific Biosciences initiated with a Buy at Canaccord
RARE Ultragenyx
$72.82 /

-0.3 (-0.41%)

01/05/22 Stifel
Stifel bullish on Ultragenyx, sees GTX-102 update as tailwind toward mid-22 data
11/03/21 Citi
Ultragenyx trading at 'significant discount to fair value,' says Citi
09/30/21 H.C. Wainwright
Ultragenyx initiated with a Buy at H.C. Wainwright
09/27/21 Piper Sandler
Piper 'incrementally positive' on Ultragenyx after clinical hold lift
RAIN Rain Therapeutics
$12.89 /

+1.39 (+12.09%)

01/03/22 Guggenheim
Rain Therapeutics price target lowered to $20 from $26 at Guggenheim
11/10/21 Piper Sandler
Rain Therapeutics price target raised to $26 from $25 at Piper Sandler
09/14/21 Goldman Sachs
Rain Therapeutics assumed with Neutral from Buy at Goldman Sachs
AMRS Amyris
$4.74 /

+0.235 (+5.22%)

11/09/21 Roth Capital
Amyris price target lowered to $15 from $22 at Roth Capital
10/14/21 Cowen
Amyris coverage transferred at Cowen
08/06/21 H.C. Wainwright
Amyris price target lowered to $30 from $35 at H.C. Wainwright
07/06/21 HSBC
Amyris is at 'tipping point on growth,' says HSBC
ALKS Alkermes
$25.01 /

+0.735 (+3.03%)

12/01/21 Citi
Alkermes initiated with a Neutral at Citi
11/09/21 Mizuho
Alkermes price target lowered to $33 from $36 at Mizuho
10/28/21 Mizuho
Alkermes shares have 25% upside after selloff, says Mizuho
10/28/21 H.C. Wainwright
Alkermes price target raised to $30 from $25 at H.C. Wainwright
NPCE NeuroPace
$10.80 /

+0.8 (+8.00%)

01/07/22 Morgan Stanley
NeuroPace cut to Underweight at Morgan Stanley on cloudy near-term outlook
01/07/22 Morgan Stanley
NeuroPace downgraded to Underweight from Equal Weight at Morgan Stanley
12/17/21 Baird
NeuroPace price target lowered to $20 from $23 at Baird
11/11/21 Morgan Stanley
Morgan Stanley downgrades NeuroPace on more uncertain recovery pace
NVRO Nevro
$91.32 /

+5.615 (+6.55%)

01/07/22 Morgan Stanley
Nevro downgraded to Equal Weight at Morgan Stanley on COVID and competition
01/07/22 Morgan Stanley
Nevro downgraded to Equal Weight from Overweight at Morgan Stanley
01/07/22 Piper Sandler
Nevro price target raised to $92 from $90 at Piper Sandler
01/04/22 Piper Sandler
Nevro shares should rally on UnitedHealthcare coverage, says Piper Sandler
SEER Seer
$20.51 /

+1.535 (+8.09%)

10/14/21 Cowen
Seer coverage transferred at Cowen
08/13/21 Morgan Stanley
Seer price target lowered to $50 from $55 at Morgan Stanley
STTK Shattuck Labs
$7.31 /

-0.06 (-0.81%)

04/14/21 Berenberg
Shattuck Labs initiated with a Buy at Berenberg
01/20/21 Citi
Shattuck Labs price target raised to $75 from $36 at Citi
TLIS Talis Biomedical
$3.30 /

+0.11 (+3.45%)

01/07/22 BofA
Talis Biomedical downgraded to Underperform from Neutral at BofA
09/27/21 JPMorgan
Talis Biomedical downgraded to Underweight from Neutral at JPMorgan
08/31/21 BTIG
Talis Biomedical downgraded to Neutral at BTIG following CEO departure
08/31/21 BTIG
Talis Biomedical downgraded to Neutral from Buy at BTIG
TXG 10x Genomics
$121.88 /

-5.76 (-4.51%)

TWST Twist Bioscience
$67.10 /

+0.57 (+0.86%)

TLIS Talis Biomedical
$3.30 /

+0.11 (+3.45%)

TDOC Teladoc
$86.25 /

+4.07 (+4.95%)

STTK Shattuck Labs
$7.31 /

-0.06 (-0.81%)

SRRK Scholar Rock
$22.04 /

+0.23 (+1.05%)

SLDB Solid Biosciences
$1.55 /

+0.02 (+1.31%)

SEER Seer
$20.51 /

+1.535 (+8.09%)

RLAY Relay Therapeutics
$27.69 /

+0.76 (+2.82%)

RARE Ultragenyx
$72.82 /

-0.3 (-0.41%)

RAIN Rain Therapeutics
$12.89 /

+1.39 (+12.09%)

QSI Quantum-Si
$6.30 /

+0.425 (+7.23%)

QDEL Quidel
$127.53 /

-3 (-2.30%)

PACB Pacific Biosciences
$14.70 /

-1.89 (-11.39%)

OMIC Singular Genomics
$8.54 /

-0.74 (-7.97%)

NVRO Nevro
$91.32 /

+5.615 (+6.55%)

NPCE NeuroPace
$10.80 /

+0.8 (+8.00%)

NOVT Novanta
$164.54 /

+5.7 (+3.59%)

MYGN Myriad Genetics
$26.57 /

+0.85 (+3.30%)

MRNS Marinus Pharmaceuticals
$11.07 /

-0.27 (-2.38%)

MOR MorphoSys
$9.19 /

+0.03 (+0.33%)

MODV ModivCare
$134.57 /

+2.57 (+1.95%)

JNJ Johnson & Johnson
$171.26 /

-1.835 (-1.06%)

JAZZ Jazz Pharmaceuticals
$149.80 /

+2.73 (+1.86%)

ITOS iTeos Therapeutics
$41.64 /

-0.18 (-0.43%)

ITCI Intra-Cellular
$40.36 /

-0.66 (-1.61%)

IART Integra LifeSciences
$67.20 /

+0.33 (+0.49%)

HZNP Horizon Therapeutics
$96.04 /

+1.06 (+1.12%)

HCAT Health Catalyst
$34.60 /

+1.17 (+3.50%)

GILD Gilead
$72.36 /

+0.28 (+0.39%)

ENDP Endo
$3.71 /

-0.055 (-1.46%)

DNA Ginkgo Bioworks
$6.83 /

+0.115 (+1.71%)

DAWN Day One Biopharmaceuticals
$15.11 /

+0.62 (+4.28%)

CRNX Crinetics
$25.49 /

+0.62 (+2.49%)

CI Cigna
$239.95 /

+6.37 (+2.73%)

CERN Cerner
$92.25 /

-0.1 (-0.11%)

BRKR Bruker
$73.05 /

-0.56 (-0.76%)

BNTX BioNTech
$215.88 /

-14.32 (-6.22%)

BHG Bright Health
$3.21 /

+0.12 (+3.88%)

BEAM Beam Therapeutics
$75.72 /

+7.3 (+10.67%)

BAX Baxter
$86.35 /

+0.02 (+0.02%)

AMRS Amyris
$4.74 /

+0.235 (+5.22%)

ALLO Allogene Therapeutics
$12.88 /

+0.68 (+5.58%)

ALKS Alkermes
$25.01 /

+0.735 (+3.03%)

ABBV AbbVie
$137.03 /

+0.64 (+0.47%)

  • 05
    Jan
  • 21
    Oct
  • 13
    Oct
  • 11
    Aug
  • 24
    Jun
  • 16
    Jun
  • 27
    May
  • 27
    May
  • 23
    Apr
  • 22
    Apr
  • 09
    Apr
  • 08
    Apr
  • 19
    Mar
  • 12
    Feb
  • 28
    Jan
SEER Seer
$20.51 /

+1.535 (+8.09%)

QDEL Quidel
$127.53 /

-3 (-2.30%)

NPCE NeuroPace
$10.80 /

+0.8 (+8.00%)

MYGN Myriad Genetics
$26.57 /

+0.85 (+3.30%)

JNJ Johnson & Johnson
$171.26 /

-1.835 (-1.06%)

HZNP Horizon Therapeutics
$96.04 /

+1.06 (+1.12%)

GILD Gilead
$72.36 /

+0.28 (+0.39%)

ENDP Endo
$3.71 /

-0.055 (-1.46%)

DNA Ginkgo Bioworks
$6.83 /

+0.115 (+1.71%)

CI Cigna
$239.95 /

+6.37 (+2.73%)

CERN Cerner
$92.25 /

-0.1 (-0.11%)

BNTX BioNTech
$215.88 /

-14.32 (-6.22%)

BAX Baxter
$86.35 /

+0.02 (+0.02%)

AMRS Amyris
$4.74 /

+0.235 (+5.22%)

ABBV AbbVie
$137.03 /

+0.64 (+0.47%)

TWST Twist Bioscience
$67.10 /

+0.57 (+0.86%)

TDOC Teladoc
$86.25 /

+4.07 (+4.95%)

SEER Seer
$20.51 /

+1.535 (+8.09%)

RLAY Relay Therapeutics
$27.69 /

+0.76 (+2.82%)

RARE Ultragenyx
$72.82 /

-0.3 (-0.41%)

QDEL Quidel
$127.53 /

-3 (-2.30%)

PACB Pacific Biosciences
$14.70 /

-1.89 (-11.39%)

NVRO Nevro
$91.32 /

+5.615 (+6.55%)

MOR MorphoSys
$9.19 /

+0.03 (+0.33%)

JNJ Johnson & Johnson
$171.26 /

-1.835 (-1.06%)

JAZZ Jazz Pharmaceuticals
$149.80 /

+2.73 (+1.86%)

ITCI Intra-Cellular
$40.36 /

-0.66 (-1.61%)

IART Integra LifeSciences
$67.20 /

+0.33 (+0.49%)

HZNP Horizon Therapeutics
$96.04 /

+1.06 (+1.12%)

HCAT Health Catalyst
$34.60 /

+1.17 (+3.50%)

GILD Gilead
$72.36 /

+0.28 (+0.39%)

ENDP Endo
$3.71 /

-0.055 (-1.46%)

DNA Ginkgo Bioworks
$6.83 /

+0.115 (+1.71%)

CRNX Crinetics
$25.49 /

+0.62 (+2.49%)

CI Cigna
$239.95 /

+6.37 (+2.73%)

CERN Cerner
$92.25 /

-0.1 (-0.11%)

BRKR Bruker
$73.05 /

-0.56 (-0.76%)

BNTX BioNTech
$215.88 /

-14.32 (-6.22%)

BHG Bright Health
$3.21 /

+0.12 (+3.88%)

BEAM Beam Therapeutics
$75.72 /

+7.3 (+10.67%)

BAX Baxter
$86.35 /

+0.02 (+0.02%)

AMRS Amyris
$4.74 /

+0.235 (+5.22%)

ALLO Allogene Therapeutics
$12.88 /

+0.68 (+5.58%)

ALKS Alkermes
$25.01 /

+0.735 (+3.03%)

ABBV AbbVie
$137.03 /

+0.64 (+0.47%)

TDOC Teladoc
$86.25 /

+4.07 (+4.95%)

STTK Shattuck Labs
$7.31 /

-0.06 (-0.81%)

PACB Pacific Biosciences
$14.70 /

-1.89 (-11.39%)

JNJ Johnson & Johnson
$171.26 /

-1.835 (-1.06%)

ITOS iTeos Therapeutics
$41.64 /

-0.18 (-0.43%)

GILD Gilead
$72.36 /

+0.28 (+0.39%)

ENDP Endo
$3.71 /

-0.055 (-1.46%)

DNA Ginkgo Bioworks
$6.83 /

+0.115 (+1.71%)

CRNX Crinetics
$25.49 /

+0.62 (+2.49%)

CI Cigna
$239.95 /

+6.37 (+2.73%)

CERN Cerner
$92.25 /

-0.1 (-0.11%)

BNTX BioNTech
$215.88 /

-14.32 (-6.22%)

BHG Bright Health
$3.21 /

+0.12 (+3.88%)

BAX Baxter
$86.35 /

+0.02 (+0.02%)

AMRS Amyris
$4.74 /

+0.235 (+5.22%)

ALLO Allogene Therapeutics
$12.88 /

+0.68 (+5.58%)

ABBV AbbVie
$137.03 /

+0.64 (+0.47%)

Recommendations
AbbVie long range estimates need to come up, says Piper Sandler » 10:21
01/11/22
01/11
10:21
01/11/22
10:21
ABBV

AbbVie

$136.12 /

-0.27 (-0.20%)

After AbbVie confirmed…

After AbbVie confirmed this morning its 2025 combined revenue guidance for Rinvoq and Skyrizi of $15B, Piper Sandler analyst Christopher Raymond noted that combined Rinvoq/Skyrizi 2025 revenue consensus stands at about $13.1B and contends that long range estimates "need to come up," adding that his combined estimate for the two drugs in 2025 is $14.8B. Given his view that the Rinvoq consensus needs to come up by about $1.5B and Skyrizi consensus needs to come up by over $400M, Raymond said this represents "meaningful upside" and he continues to identify AbbVie as his top large-cap pick. Raymond keeps an Overweight rating and $160 price target on AbbVie shares.

ShowHide Related Items >><<
ABBV AbbVie
$136.12 /

-0.27 (-0.20%)

ABBV AbbVie
$136.12 /

-0.27 (-0.20%)

01/05/22 Mizuho
Mizuho keeps AbbVie as top 2022 large cap pick, ups target
01/03/22 Piper Sandler
AbbVie price target raised to $160 from $129 at Piper Sandler
12/17/21 Goldman Sachs
AbbVie initiated with a Neutral at Goldman Sachs
12/08/21 Wells Fargo
Vertex Pharmaceuticals initiated with an Overweight at Wells Fargo
ABBV AbbVie
$136.12 /

-0.27 (-0.20%)

ABBV AbbVie
$136.12 /

-0.27 (-0.20%)

ABBV AbbVie
$136.12 /

-0.27 (-0.20%)

ABBV AbbVie
$136.12 /

-0.27 (-0.20%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.